Chandni Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chandni Patel has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Bradley J. Monk
Florida Cancer Specialists & Research Institute West Palm Beach Florida USA
1 shared publicationChristina White
Florida Cancer Specialists & Research Institute Ocala Florida USA
1 shared publicationCrystal Clark
Florida Cancer Specialists & Research Institute Trinity Florida USA
1 shared publication- Eveline Hürlimann
Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Allschwil, Switzerland
1 shared publication - Gigi A. Gonzales
Florida Cancer Specialists & Research Institute Port Charlotte Florida USA
1 shared publication - Gustavo Fonseca
Florida Cancer Specialists & Research Institute Lecanto Florida USA
1 shared publication
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (8) , e70572
Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study
Background: Participation in cancer clinical trials is essential for advancing oncologic care, yet enrollment among rural populations remains disproportionately low. These communities face many hurdles including geographical distance from medical centers, healthcare workforce shortages, and deep‐seated medical mistrust that may contribute to survival inequities. Aims: To address these gaps, a Research Navigator program was launched through the Florida Cancer Specialists & Research Institute to engage rural Florida residents in focus group sessions to identify barriers to trial participation. Methods: Utilizing the Integrated Behavioral and Socioecological Framework (IBSF), the study conducted five semi‐structured focus groups with 30 participants recruited from rural Florida counties. Participants included cancer survivors, advocates, caregivers, and those currently in treatment. Discussions centered on knowledge, experiences, perceived barriers, and willingness to participate in cancer clinical trials. Results: Although most participants expressed awareness of cancer clinical trials, focus group discussions revealed misconceptions regarding trial purpose, process, and accessibility. Across groups, commonly reported barriers to participation included limited access to reliable transportation, financial concerns, and mistrust of medical professionals and healthcare systems. Thematic analysis of focus group transcripts yielded four themes: (A) perception and lived experience, (B) trial information dissemination, (C) enrollment impediments, and (D) intervention strategies and implementation. Conclusion: In rural settings, decisions regarding cancer clinical trial participation are shaped by a complex interplay of trust, logistics, and information access. This study emphasizes the importance of viewing trials as routine care and suggests that navigator‐led outreach and patient‐centric technology are essential for creating equitable access.
- 9 August 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (8) , e70572
Open AccessUnderstanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study
Background: Participation in cancer clinical trials is essential for advancing oncologic care, yet enrollment among rural populations remains disproportionately low. These communities face many hurdles including geographical distance from medical centers, healthcare workforce shortages, and deep‐seated medical mistrust that may contribute to survival inequities. Aims: To address these gaps, a Research Navigator program was launched through the Florida Cancer Specialists & Research Institute to engage rural Florida residents in focus group sessions to identify barriers to trial participation. Methods: Utilizing the Integrated Behavioral and Socioecological Framework (IBSF), the study conducted five semi‐structured focus groups with 30 participants recruited from rural Florida counties. Participants included cancer survivors, advocates, caregivers, and those currently in treatment. Discussions centered on knowledge, experiences, perceived barriers, and willingness to participate in cancer clinical trials. Results: Although most participants expressed awareness of cancer clinical trials, focus group discussions revealed misconceptions regarding trial purpose, process, and accessibility. Across groups, commonly reported barriers to participation included limited access to reliable transportation, financial concerns, and mistrust of medical professionals and healthcare systems. Thematic analysis of focus group transcripts yielded four themes: (A) perception and lived experience, (B) trial information dissemination, (C) enrollment impediments, and (D) intervention strategies and implementation. Conclusion: In rural settings, decisions regarding cancer clinical trial participation are shaped by a complex interplay of trust, logistics, and information access. This study emphasizes the importance of viewing trials as routine care and suggests that navigator‐led outreach and patient‐centric technology are essential for creating equitable access.
- Open Access
- 30 June 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (6) , e0009561
Long-term outcomes of ivermectin-albendazole versus albendazole alone against soil-transmitted helminths: Results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania
Background: Preventive chemotherapy is the cornerstone of soil-transmitted helminth (STH) control. Long-term outcomes and adequate treatment frequency of the recently recommended albendazole-ivermectin have not been studied to date. Methodology/principal findings: Double-blind randomized controlled trials were conducted in Lao PDR, Pemba Island, Tanzania and Côte d’Ivoire between 2018 and 2020 to evaluate the efficacy and safety of ivermectin-albendazole versus albendazole-placebo in Trichuris trichiura-infected individuals aged 6 to 60. In the framework of this study, in Lao PDR 466 and 413 participants and on Pemba Island, 558 and 515 participants were followed-up six and 12 months post-treatment, respectively. From each participant at least one stool sample was processed for Kato-Katz diagnosis and cure rates (CRs), egg reduction rates (ERRs) and apparent reinfection rates were calculated. If found helminth-positive at six months, participants were re-treated according to their allocated treatment. Long-term outcomes against T. trichiura based on CRs and ERRs of ivermectin-albendazole compared to albendazole were significantly higher at six months in Lao PDR (CR, 65.8 vs 13.4%, difference; 52.4; 95% CI 45.0–60.0; ERRs, 99.0 vs 79.6, difference 19.4; 95% CI 14.4–24.4) and Pemba Island (CR, 17.8 vs 1.4%, difference; 16.4; 95% CI 11.6–21.0; ERRs, 84.9 vs 21.2, difference 63.8; 95% CI 50.6–76.9) and also at 12 months in Lao PDR (CR, 74.0 vs 23.4%, difference; 50.6; 95% CI 42.6–61.0; ERRs, 99.6 vs 91.3, difference 8.3; 95% CI 5.7–10.8) and Pemba Island (CR, 19.5 vs 3.4%, difference; 16.1; 95% CI 10.7–21.5; ERRs, 92.9 vs 53.6, difference 39.3; 95% CI 31.2–47.4) respectively. Apparent reinfection rates with T. trichiura were considerably higher on Pemba Island (100.0%, 95% CI, 29.2–100.0) than in Lao PDR (10.0%, 95% CI, 0.2–44.5) at 12 months post-treatment for participants treated with albendazole alone. Conclusions/significance: The long-term outcomes against T. trichiura of ivermectin-albendazole are superior to albendazole in terms of CRs and ERRs and in reducing infection intensities. Our results will help to guide decisions on how to best use ivermectin-albendazole in the context of large-scale PC programs tailored to the local context to sustainably control STH infections. Trial registration: ClinicalTrials.gov registered with clinicaltrials.gov, reference: NCT03527732, date assigned: 17 May 2018.
- 30 June 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (6) , e0009561
Open AccessLong-term outcomes of ivermectin-albendazole versus albendazole alone against soil-transmitted helminths: Results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania
Background: Preventive chemotherapy is the cornerstone of soil-transmitted helminth (STH) control. Long-term outcomes and adequate treatment frequency of the recently recommended albendazole-ivermectin have not been studied to date. Methodology/principal findings: Double-blind randomized controlled trials were conducted in Lao PDR, Pemba Island, Tanzania and Côte d’Ivoire between 2018 and 2020 to evaluate the efficacy and safety of ivermectin-albendazole versus albendazole-placebo in Trichuris trichiura-infected individuals aged 6 to 60. In the framework of this study, in Lao PDR 466 and 413 participants and on Pemba Island, 558 and 515 participants were followed-up six and 12 months post-treatment, respectively. From each participant at least one stool sample was processed for Kato-Katz diagnosis and cure rates (CRs), egg reduction rates (ERRs) and apparent reinfection rates were calculated. If found helminth-positive at six months, participants were re-treated according to their allocated treatment. Long-term outcomes against T. trichiura based on CRs and ERRs of ivermectin-albendazole compared to albendazole were significantly higher at six months in Lao PDR (CR, 65.8 vs 13.4%, difference; 52.4; 95% CI 45.0–60.0; ERRs, 99.0 vs 79.6, difference 19.4; 95% CI 14.4–24.4) and Pemba Island (CR, 17.8 vs 1.4%, difference; 16.4; 95% CI 11.6–21.0; ERRs, 84.9 vs 21.2, difference 63.8; 95% CI 50.6–76.9) and also at 12 months in Lao PDR (CR, 74.0 vs 23.4%, difference; 50.6; 95% CI 42.6–61.0; ERRs, 99.6 vs 91.3, difference 8.3; 95% CI 5.7–10.8) and Pemba Island (CR, 19.5 vs 3.4%, difference; 16.1; 95% CI 10.7–21.5; ERRs, 92.9 vs 53.6, difference 39.3; 95% CI 31.2–47.4) respectively. Apparent reinfection rates with T. trichiura were considerably higher on Pemba Island (100.0%, 95% CI, 29.2–100.0) than in Lao PDR (10.0%, 95% CI, 0.2–44.5) at 12 months post-treatment for participants treated with albendazole alone. Conclusions/significance: The long-term outcomes against T. trichiura of ivermectin-albendazole are superior to albendazole in terms of CRs and ERRs and in reducing infection intensities. Our results will help to guide decisions on how to best use ivermectin-albendazole in the context of large-scale PC programs tailored to the local context to sustainably control STH infections. Trial registration: ClinicalTrials.gov registered with clinicaltrials.gov, reference: NCT03527732, date assigned: 17 May 2018.